Alteogen Inc.
196170
Rankning i aktier
#1837
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aktiekurs
$165.61
Marknadsvärde
$11.53B
Förändring (1 dag)
4.13%
Förändring (1 år)
-46.48%
Land
KR
Handel Alteogen Inc. (196170)
Kategori
Healthcare
Antal utestående aktier för Alteogen Inc. (196170)
Antal utestående aktier per June 2026: 73.51M
Enligt de senaste finansiella rapporterna och aktiekursen för Alteogen Inc. är det aktuella antalet utestående aktier 73.51M. I slutet av December 2023 hade företaget 51.66M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Alteogen Inc. (196170) från 2012 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 73.51M | 38.40% |
| 2024 | 53.12M | 2.82% |
| 2023 | 51.66M | 0.74% |
| 2022 | 51.28M | -15.57% |
| 2021 | 60.74M | 20.48% |
| 2020 | 50.41M | 4.62% |
| 2019 | 48.19M | 5.97% |
| 2018 | 45.47M | 1.22% |
| 2017 | 44.92M | 3.62% |
| 2016 | 43.36M | 2.60% |
| 2015 | 42.26M | 34.26% |
| 2014 | 31.48M | 64.68% |
| 2013 | 19.11M | 15.04% |
| 2012 | 16.61M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 245.39% |
US
|
|
| 396.00M | 438.69% |
US
|
|
| 478.91M | 551.48% |
AU
|
|
| 62.19M | -15.41% |
NL
|
|
| - | - |
CH
|
